在2型高度统一气道疾病中使用家庭监测评估度普利尤单抗早期反应的起效和消退情况 - Suppr

Suppr

超能文献

Onset and Offset of Early Dupilumab Response Using Domiciliary Monitoring in Type 2 High Unified Airway Disease.

作者信息

Stewart Kirsten, Kuo Chris RuiWen, Chan Rory, Lipworth Brian

机构信息

Scottish Centre for Respiratory Research, School of Medicine, University of Dundee, Ninewells Hospital, Dundee, UK.

出版信息

Clin Exp Allergy. 2024 Dec;54(12):1010-1012. doi: 10.1111/cea.14550. Epub 2024 Aug 13.

DOI:10.1111/cea.14550

PMID:39138649

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11629044/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38b2/11629044/7fd10b6f61c6/CEA-54-1010-g001.jpg

相似文献

Onset and Offset of Early Dupilumab Response Using Domiciliary Monitoring in Type 2 High Unified Airway Disease.在2型高度统一气道疾病中使用家庭监测评估度普利尤单抗早期反应的起效和消退情况

Clin Exp Allergy. 2024 Dec;54(12):1010-1012. doi: 10.1111/cea.14550. Epub 2024 Aug 13.

Biologics for chronic rhinosinusitis.用于慢性鼻-鼻窦炎的生物制剂。

Cochrane Database Syst Rev. 2020 Feb 27;2(2):CD013513. doi: 10.1002/14651858.CD013513.pub2.

Very Rapid Improvement in Extended Nitric Oxide Parameters Is Associated With Clinical and Functional Improvement in Patients With Chronic Rhinosinusitis With Nasal Polyps Treated With Dupilumab.度普利尤单抗治疗慢性鼻-鼻窦炎伴鼻息肉患者中，延长的一氧化氮参数的快速改善与临床和功能改善相关。

J Investig Allergol Clin Immunol. 2023 Dec;33(6):457-463. doi: 10.18176/jiaci.0851. Epub 2022 Sep 1.

Efficacy of dupilumab on chronic rhinosinusitis with nasal polyps and concomitant asthma in biologic-naive and biologic-pretreated patients.度普利尤单抗治疗生物制剂初治和生物制剂预处理的慢性鼻-鼻窦炎伴鼻息肉和哮喘患者的疗效。

Ann Med. 2024 Dec;56(1):2411018. doi: 10.1080/07853890.2024.2411018. Epub 2024 Oct 4.

Efficacy of dupilumab for severe chronic rhinosinusitis with nasal polyps and asthma: A prospective study.度普利尤单抗治疗伴有鼻息肉和哮喘的重度慢性鼻-鼻窦炎的疗效：一项前瞻性研究。

Ann Allergy Asthma Immunol. 2024 Nov;133(5):550-558.e2. doi: 10.1016/j.anai.2024.07.001. Epub 2024 Jul 6.

Real-world effectiveness of dupilumab in a European cohort of chronic rhinosinusitis with nasal polyps (CHRINOSOR).度普利尤单抗在欧洲慢性鼻-鼻窦炎伴鼻息肉队列（CHRINOSOR）中的真实世界疗效

J Allergy Clin Immunol. 2025 Feb;155(2):451-460. doi: 10.1016/j.jaci.2024.10.016. Epub 2024 Oct 31.

Biologics for chronic rhinosinusitis.生物制剂治疗慢性鼻-鼻窦炎。

Cochrane Database Syst Rev. 2021 Mar 12;3(3):CD013513. doi: 10.1002/14651858.CD013513.pub3.

Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma.度普利尤单抗可改善伴有鼻息肉和哮喘的慢性鼻-鼻窦炎的上、下气道疾病控制。

Ann Allergy Asthma Immunol. 2021 May;126(5):584-592.e1. doi: 10.1016/j.anai.2021.01.012. Epub 2021 Jan 16.

Comorbid asthma in patients with chronic rhinosinusitis with nasal polyps: did dupilumab make a difference?慢性鼻-鼻窦炎伴鼻息肉患者的合并哮喘：度普利尤单抗是否有影响？

BMC Pulm Med. 2023 Jul 18;23(1):266. doi: 10.1186/s12890-023-02556-8.

Long-Term Effectiveness of Dupilumab in Severe Uncontrolled Chronic Rhinosinusitis with Nasal Polyps: A Multicenter Retrospective Study.度普利尤单抗治疗严重难治性慢性鼻-鼻窦炎伴鼻息肉的长期疗效：一项多中心回顾性研究

Am J Rhinol Allergy. 2025 May;39(3):175-180. doi: 10.1177/19458924251313493. Epub 2025 Jan 15.

本文引用的文献

Meaningful changes for efficacy outcomes in patients with chronic rhinosinusitis with nasal polyps.伴有鼻息肉的慢性鼻窦炎患者疗效结局的有意义变化。

World Allergy Organ J. 2023 May 13;16(5):100776. doi: 10.1016/j.waojou.2023.100776. eCollection 2023 May.

Anti-inflammatory reliever therapy for asthma.哮喘的抗炎缓解疗法。

Ann Allergy Asthma Immunol. 2020 Jan;124(1):13-15. doi: 10.1016/j.anai.2019.10.002. Epub 2019 Oct 11.

Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.度普利尤单抗治疗伴有鼻息肉的重度慢性鼻-鼻窦炎患者的疗效和安全性（LIBERTY NP SINUS-24 和 LIBERTY NP SINUS-52）：两项多中心、随机、双盲、安慰剂对照、平行分组 3 期临床试验的结果。

Lancet. 2019 Nov 2;394(10209):1638-1650. doi: 10.1016/S0140-6736(19)31881-1. Epub 2019 Sep 19.

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.度普利尤单抗在中重度未控制哮喘中的疗效和安全性。

N Engl J Med. 2018 Jun 28;378(26):2486-2496. doi: 10.1056/NEJMoa1804092. Epub 2018 May 21.

Investigating the minimal clinically important difference for SNOT-22 symptom domains in surgically managed chronic rhinosinusitis.调查手术治疗慢性鼻-鼻窦炎患者 SNOT-22 症状领域的最小临床重要差异。

Int Forum Allergy Rhinol. 2017 Dec;7(12):1149-1155. doi: 10.1002/alr.22028. Epub 2017 Oct 20.

Visual analogue scales (VAS): Measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care: Position Paper of the German Society of Allergology (AeDA) and the German Society of Allergy and Clinical Immunology (DGAKI), ENT Section, in collaboration with the working group on Clinical Immunology, Allergology and Environmental Medicine of the German Society of Otorhinolaryngology, Head and Neck Surgery (DGHNOKHC).视觉模拟量表（VAS）：用于日常医疗中过敏性鼻炎症状记录和治疗监测的测量工具：德国变态反应学会（AeDA）和德国变态反应与临床免疫学会（DGAKI）耳鼻喉科分会与德国耳鼻咽喉头颈外科学会（DGHNOKHC）临床免疫学、变态反应学和环境医学工作组合作发表的立场文件

Allergo J Int. 2017;26(1):16-24. doi: 10.1007/s40629-016-0006-7. Epub 2017 Jan 19.

Minimal clinically important differences in nasal peak inspiratory flow.鼻峰吸气流量的最小临床重要差异。

Rhinology. 2011 Mar;49(1):37-40. doi: 10.4193/Rhino10.097.

Measurement properties and interpretation of three shortened versions of the asthma control questionnaire.哮喘控制问卷三个简化版本的测量属性及解读

Respir Med. 2005 May;99(5):553-8. doi: 10.1016/j.rmed.2004.10.008. Epub 2004 Nov 26.

What are minimal important changes for asthma measures in a clinical trial?在临床试验中，哮喘测量的最小重要变化是什么？

Eur Respir J. 1999 Jul;14(1):23-7. doi: 10.1034/j.1399-3003.1999.14a06.x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验